Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.
Commentary|Articles|July 29, 2026
The Great 340B Debate: What Pharmacists Need to Know
Author(s)Brian Nowosielski
Tom Kraus, JD, of ASHP, and Shawn Gremminger, MPP, of the National Alliance of Healthcare Purchaser Coalitions, face off on the 340B Drug Pricing Program.
Advertisement
Advertisement
The 340B Drug Pricing Program has quietly grown into one of the largest, most contested financial arrangements in the American health care ecosystem. For pharmacists, they sit closer to its mechanics than almost any other industry stakeholder, making this group of providers key in systematic conversations regarding the program’s future.
Related to this article
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.
In this episode, Shawn Bjorndal, PharmD, RPh, and Jesse McCullough, PharmD, explore rhythms, routines and how they can make or break pharmacy team members.
Vanessa Slowey lays the ground for where AI and automation are impacting pharmacy practice today and discusses what innovations are still expected.
Thomas Lew, MD, ABIM, Molly O’Shea, MD, FAAP, and Jesse Goodman, MD, MPH, discuss vaccine policy changes and their impact on measles outbreaks.
Advertisement
Advertisement